Kód: 04579311
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studi ... celý popis
1950 Kč
Dostupnost:
50 % šanceMáme informaci, že by titul mohl být dostupný. Na základě vaší objednávky se ho pokusíme do 6 týdnů zajistit.Zadejte do formuláře e-mailovou adresu a jakmile knihu naskladníme, zašleme vám o tom zprávu. Pohlídáme vše za vás.
Nákupem získáte 195 bodů
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Zařazení knihy Knihy v angličtině Medicine Clinical & internal medicine Paediatric medicine
1950 Kč
Osobní odběr Praha, Brno a 12903 dalších
Copyright ©2008-24 nejlevnejsi-knihy.cz Všechna práva vyhrazenaSoukromíCookies
Nákupní košík ( prázdný )